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Holistic	Needs	Assessment	in	Brain	
Cancer	Patients:	A	Systematic	Review	
of	Available	Tools	
Introduction	
A	diagnosis	of	brain	cancer	affects	nearly	10	000	adults	per	year	in	the	United	
Kingdom	and	has	a	devastating	impact	on	individuals	and	their	significant	others	
(Cancer	Research	UK,	2015b).	Gliomas	are	the	most	common	type	of	primary	intra-
cerebral	cancer	and	constitute	approximately	75%	of	cases	(Taphoorn	et	al.,	2010).	
Of	these		>	60%	are	high	grade	Glioblastoma	Multiforme	(GBM)	that	has	a	median	
survival	of	12	months	(Hayat,	2011).		Although	40-50%	of	brain	cancers	occur	in	the	>	
60	year	age	range,	compared	to	most	other	cancers,	the	incidence	is	more	widely	
distributed	across	all	ages	groups.	There	is	a	significant	impact	on	younger	adults	due	
to	poor	survival	rate	and	the	age	at	which	brain	cancer	occurs	(Cancer	Research	UK,	
2015a).		Therefore,	brain	cancer	is	the	most	common	cause	of	death	from	solid	
cancers	in	the	16-24	year	old	age	range	and	the	second	most	common	cancer	death	
in	adults		in	the	25-49	years	old	age	range	in	the	UK	(Cancer	Research	UK,	2015c).		
Brain	cancer	differs	significantly	from	other	cancers	due	to	the	unique	
neurocognitive	symptoms	and	higher	symptom	burden	(Ford,	Catt,	Chalmers,	&	
Fallowfield,	2012).	Upon	diagnosis,	patients	must	deal	with	the	implications	of	a	life	
limiting	illness	whilst	coping	with	the	symptoms,	which	can	be	severe	and	
progressive	(Cavers	et	al.,	2012).	Approximately	50%	of	patients	present	with	
headaches,	and	other	common	symptoms	include	confusion,	hemiparesis,	gait	
imbalance,	language	difficulties	personality	changes,	mood	disturbance	(e.g.	anxiety,	
fatigue,	depression),	decreases	in	mental	capacity,	and	problems	with	concentration	
(Butowski	&	Chang,	2007;	Catt,	Chalmers,	&	Fallowfield,	2008;	Janda	et	al.,	2008;	
Omuro	&	DeAngelis,	2013).	Seizures	are	common	with	rates	of	up	to	60–75%	for	
individuals	diagnosed	with	low-grade	gliomas	and	25–60%	with	high-grade	gliomas.		
This	may	impact	employment,	social	interactions	and	independence	(Englot,	Chang,	
&	Vecht,	2016).	Patients	have	self-reported	behavioural	changes	such	as	disinhibition	
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(19%),	anger	(27%),	inappropriate	behaviour	(27%)	or	apathy	(41%)	(Simpson	et	al.,	
2015).	This	presents	significant	challenges	for	the	patients	and	their	carers.	
Treatment	options	in	brain	cancer	can	cause	multiple	local	and	general	side	effects.	
Patients	undergoing	brain	radiotherapy	will	typically	have	a	number	of	side	effects	
including	hair	loss,	nausea	and	fatigue.	They	also	frequently	suffer	cognitive	
symptoms	related	to	the	area	of	the	brain	being	treated	due	to	injury	and	swelling	
(Grant,	2004).	Similarly,	the	common	side	effects	of	chemotherapy	include	
haematological	toxicity,	fatigue,	nausea	and	vomiting,	rash	and	impaired	liver	
function	(Omuro	&	DeAngelis,	2013).	Other	treatments	such	as	steroids,	used	to	
reduce	brain	swelling,	can	result	in	myopathy,	hyperglycaemia,	personality	change,	
weight	gain	and	insomnia	(Dietrich,	Rao,	Pastorino,	&	Kesari,	2011).		There	are	also	
numerous	common	side	effects	from	antiepileptic	drugs	such	as	fatigue,	nausea,	
dizziness	or	visual	disturbances	and	these	may	be	more	pronounced	and	common	in	
patients	with	brain	tumours	(Perucca,	2013).		Identifying	the	problems	that	impact	
patients	and	their	families	is	an	important	first	step	in	providing	supportive	care.	
Numerous	studies	and	reviews	have	demonstrated	high	levels	of	unmet	needs	in	
cancer	patients.	These	include	lack	of	support	in	managing	anxiety,	depression	and	
fatigue	or	lack	of	information	(Barg	et	al.,	2007;	Harrison,	Young,	Price,	Butow,	&	
Solomon,	2009;	Hwang	et	al.,	2004;	Janda	et	al.,	2008;	McDowell,	Occhipinti,	
Ferguson,	Dunn,	&	Chambers,	2010;	Pigott,	Pollard,	Thomson,	&	Aranda,	2009;	Puts,	
Papoutsis,	Springall,	&	Tourangeau,	2012;	Sanders,	Bantum,	Owen,	Thornton,	&	
Stanton,	2010).	However	patients	often	do	not	communicate	psychological	concerns	
to	their	clinicians	(Wen	&	Gustafson,	2004)	and	there	is	evidence	that	health	care	
professionals	may	not	detect	emotional	distress	(Mitchell,	Hussain,	Grainger,	&	
Symonds,	2011).		The	lack	of	detection	of	needs	for	all	cancers	is	problematic,	but	
possibly	more	significant	in	patients	with	brain	cancers,	as	they	have	one	of	the	
highest	rates	of	depression	(Hartung	et	al.,	2017)	and	this	in	combination	with	their	
significant	and	unique	needs,	necessitate	targeted	mechanisms	to	deliver	
appropriate	supportive	care.	
Holistic	needs	assessment	(HNA)	has	been	widely	used	to	identify	concerns	and	
unmet	needs	in	many	cancers	(National	Cancer	Action	Team,	2012).		HNA	typically	
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includes	a	review	of	physical,	psychological	or	emotional,	spiritual,	social,	practical	
and	other	domains	of	needs	to	provide	a	systemic	assessment	which	can	aid	in	
planning	appropriate	supportive	care	or	referrals		(Richardson,	Medina,	Brown,	&	
Sitzia,	2007).	There	are	numerous	tools	that	are	commonly	used	for	HNA	across	all	
cancer	types	such	as,	the	Sheffield	Profile	for	Assessment	and	Referral	to	Care	
(SPARC)	(Ahmed,	Ahmedzai,	Collins,	&	Noble,	2014),	National	Comprehensive	Cancer	
Network	(NCCN)	Distress	thermometer	and	concerns	checklist	(National	
Comprehensive	Cancer	Network,	2013)	or	the	Macmillan	electronic	HNA	(Ipsos	Mori,	
2013).		However,	it	has	been	suggested	these	are	not	suitable	for	brain	cancers	due	
to	the	unique	needs	of	these	patients,	as	they	lack	specificity	and	sensitivity	in	
assessing	needs	such	as	neurocognitive	symptoms,	which	are	often	most	significant	
problems	(Armstrong,	Cohen,	Eriksen,	&	Cleeland,	2005;	Dirven	et	al.,	2018;	Janda,	
Eakin,	Bailey,	Walker,	&	Troy,	2006;	Rooney	et	al.,	2014).		Cognitive	impairments	may	
present	additional	challenges	for	this	population	to	complete	patient	reported	
outcome	measures	(PROMs).	Therefore,	it	is	important	that	the	development	of	
tools	includes	individuals	with	brain	cancers	to	assess	user	comprehension	and	
acceptability	(e.g.	length	and	format).		
The	aim	of	the	review	is	to	systematically	identify	and	evaluate	the	psychometric	
properties	and	clinical	utility	of	tools	that	assess	needs,	problems	or	concerns	in	
brain	cancer	patients.		We	sought	to	identify	tools	that	were	developed	and	tested	
specifically	on	a	brain	cancer	population	which	could	be	used	to	support	HNA.	We	
defined	HNA	tools	as	those	that	identified	an	unmet	need	that	prevented	optimal	
wellbeing.	The	tools	needed	to	look	at	a	minimum	of	two	of	the	domains	of	need	in	
the	categories	of	physical,	psychological	or	emotional,	spiritual,	practical	or	social	
needs.	The	search	was	focused	on	tools	designed	to	assess	need	in	clinical	care	as	
opposed	to	outcome	measurements	purely	for	clinical	research.	This	did	include	
those	classified	as	‘symptom’	assessment	measures	as	these	have	been	suggested	
and	used	as	a	strategy	to	support	problem	identification	(Canadian	Partnership	
Against	Cancer,	2012;	Watanabe,	Nekolaichuk,	&	Beaumont,	2012).		
Methods	
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A	systematic	literature	search	was	undertaken	in	February	2018.	The	following	
electronic	databases	were	searched:	MEDLINE,	Cumulative	Index	to	Nursing	and	
Allied	Health	Literature	(CINAHL),	and	PsycINFO.	This	was	to	identify	the	literature	
which	reported	the	development,	psychometric	testing	or	clinical	utility	testing	of	
tools	that	were	developed	as	a	PROM	and	undertake	need	or	symptom	assessments	
in	brain	cancer.	The	search	strategy	aimed	at	including	all	relevant	literature;	but	was	
limited	to	the	most	common	databases,	studies	on	humans	and	studies	on	adults.		
The	following	search	terms	were	included:	
(Needs	Assessment)	OR	(Symptom	Assessment)	OR	(Self-Assessment)	OR	(Patient	
Outcome	Assessment)	OR	(inventory	or	tool*	or	measure*	or	instrument*)	AND	
(Brain	Neoplasms).		Dependant	on	the	database,	Subject	Headings	which	
encompassed	relevant	concepts	were	used	or	some	terms	were	limited	to	abstract	
and	title	to	improve	the	sensitivity	and	specificity.	The	search	strategy	was	devised	
by	a	healthcare	librarian	and	one	of	the	authors	(JA).	The	search	strategy	for	
MEDLINE	is	presented	in	the	online	supporting	information	(Appendix	S1).	Citations	
from	relevant	research	articles	or	systematic	reviews	of	cancer	HNA	tools	were	
reviewed	for	potential	relevant	research	studies.		The	corresponding	authors	of	the	
relevant	tools	were	contacted	to	request	additional	information.		
Study	Selection	
Each	paper	was	assessed	for	relevance	by	JA	using	the	following	inclusion	and	
exclusion	criteria.	Inclusion	criteria	included	primary	research	published	in	English	
which	reported	the	development,	psychometric	testing	or	clinical	utility	testing	of	
PROMs	for	the	assessment	of	adult	(age	>	18)	brain	cancer	patients’	needs	or	generic	
cancer	needs	assessment	tools	developed	specifically	on	a	brain	cancer	or	brain	
tumour	population.	Studies	that	included	benign	brain	tumours	as	well	as	brain	
cancers	were	included	due	to	the	similar	symptom	profile.		Articles	needed	to	be	
published	as	full	text	article	as	recommended	by	the	COSMIN	protocol	for	systematic	
reviews	of	measurement	properties	(Terwee,	de	Vet,	Prinsen,	&	Mokkink,	2011).	
However,	we	excluded	studies	which	only	included	patients	who	have	brain	
metastasis	due	to	the	differing	symptom	profile	which	would	be	present	due	to	their	
underlying	primary	cancer	diagnosis.			Tools	were	selected	that	identified	unmet	
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needs,	concerns	or	problems.		All	literature	that	contributed	to	the	development	of	
‘brain	specific’	content	of	a	needs	assessment	tool,	was	included	in	the	review.	The	
tools	had	to	have	been	developed	for	completion	by	patients.		There	were	no	date	
limits	to	ensure	all	development	studies	were	included.		Exclusion	criteria	were	any	
other	PROMs	which	do	not	measure	needs	(for	example	health	related	quality	of	life	
(QOL)	or	satisfaction)	or	those	that	only	looked	at	only	one	aspect	of	need	(for	
example	information	needs).	
Data	extraction	and	quality	appraisal	strategy	
	
Data	from	the	selected	studies	was	extracted	using	standardised	forms.		The	tool	
characteristics	are	presented	in	Table	1	and	the	data	which	represented	the	
psychometric	properties	of	the	tools	is	summarised	in	Table	2.	This	information	was	
then	used	to	support	the	evaluation	of	each	of	the	tools	psychometric	properties	and	
use	as	an	HNA	tool.		
To	evaluate	the	psychometric	properties	of	each	identified	tool,	the	‘Consensus-
based	Standards	for	the	selection	of	health	Measurement	INstruments’	or	COSMIN	
checklist	was	used	(Mokkink	et	al.,	2006;	Mokkink	et	al.,	2010).		This	checklist	was	
developed	through	a	Delphi	study	of	57	international	experts	to	help	select	an	
instrument	for	use,	to	review	studies,	to	design	or	report	the	measurement	
properties	of	a	new	tool	(Mokkink	et	al.,	2010).	This	checklist	provides		evaluation	
criteria	for	psychometric	properties	(Mokkink	et	al.,	2010)	which	are	then	given	a	
rating	of	excellent,	good,	fair,	poor	or	not	assessed	by	taking	the	lowest	rating	of	any	
of	the	items	that	make	up	each	attribute	(Terwee	et	al.,	2012).		Interpretability	and	
generalizability	are	not	rated	but	a	list	of	considerations	is	provided	as	no	scoring	
criteria	was	developed	for	these	properties	(Terwee	et	al.,	2012).		A	description	of	
the	psychometric	properties	is	provided	(Box	1).	
Three	studies	have	proposed	evaluation	criteria	for	HNA	tools,	which	were	used	in	
systematic	reviews	and	research	(Bonevski	et	al.,	2000;	Richardson	et	al.,	2007;	Wen	
&	Gustafson,	2004).			To	undertake	the	appraisal	of	the	tools	for	use	as	a	HNA,	these	
were	used	to	formulate	the	criteria	used	in	this	review.		These	publications	all	
included	the	need	for	good	psychometric	properties	focused	on	validity	and	
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reliability,	a	consideration	of	user	acceptability	for	patients	and	those	administering	
and	interpreting	the	results.		All	authors	in	their	proposed	criteria	mentioned	tools	
should	capture	the	holistic	dimensions	of	need	-	although	the	exact	criteria	varied.		
Ratings	based	on	these	criteria	were	determined	as	detailed	in	Box	2.		
Results	
The	search	was	undertaken	from	01	February	2018	to	27	February	2018	and	this	
process	is	illustrated	in	Figure	1.	The	total	number	of	articles	identified	using	the	
search	criteria	was	5901	and	526	duplicates	were	removed	leaving	5375	articles	to	
screen.	After	reviewing	titles	and	abstracts	there	were	142	remaining	articles	
screened	by	full	text	and	8	were	included	in	the	review.	Reference	lists	were	
reviewed	to	search	for	any	additional	relevant	citations	and	none	were	found.	
Corresponding	authors	of	tools	were	contacted	and	this	process	provided	one	other	
relevant	paper.	 
In	total,	nine	articles	were	identified	describing	four	tools,	which	have	the	potential	
to	assess	needs,	problems	or	concerns	in	brain	cancer	patients	and	a	summary	of	
their	characteristics	is	presented	in	Table	1.	These	were	the	Supportive	Care	Needs	
Survey	34	plus	brain	subscale	(SCNS34-BS);	MD	Anderson	Symptom	Inventory	–	Brain	
Tumor	Module	(MDASI-BT);	Brain	Patient	Concern	Inventory	(PCI);	and	the	National	
Comprehensive	Cancer	Network/Functional	Assessment	of	Cancer	Therapy-Brain	
Symptom	Index	(NFbrSI-24)	and	the	studies	which	developed	these	tools	are	detailed	
in	the	following	section.		
Summary	of	tools	and	the	developmental	studies	
Brain	Patient	Concern	Inventory		
There	was	only	one	study	which	reported	the	development	of	the	Brain	PCI	(Rooney	
et	al.,	2014).		This	study	described	the	process	for	questionnaire	design,	however,	
the	number	of	healthcare	professionals	or	geographical	location	was	not	specified	
for	those	involved	in	developing	content.		In	the	assessment	of	user	acceptability,	45	
patients	were	recruited	from	a	cancer	centre	in	Scotland.	In	addition,	21	feedback	
forms	were	obtained	from	healthcare	professionals	in	this	centre	but	it	was	unclear	
how	many	participants	were	involved	(Rooney	et	al.,	2014).		
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MD	Anderson	Symptom	Inventory	–	Brain	Tumor	Module		
There	were	four	studies	that	reported	the	development	of	the	MDASI-BT	for	clinical	
and	research	purposes.		The	first	study	undertook	item	generation	and	content	
validity	(Armstrong	et	al.,	2005),	the	second	focused	on	reliability	and	validity	testing	
(Armstrong	et	al.,	2006),	and	two	studies	looked	at	the	test-retest	reliability	
(Armstrong,	Vera-Bolanos,	Acquaye,	Gilbert,	&	Mendoza,	2014;	Armstrong	et	al.,	
2012).		All	participants	for	all	studies	were	recruited	from	a	large	cancer	centre	in	
Texas,	with	the	exception	of	the	inclusion	of	experts	recruited	to	develop	content	
validity	with	50%	recruited	out	with	the	institution	(Armstrong	et	al.,	2005).			
National	Comprehensive	Cancer	Network/Functional	Assessment	of	Cancer	Therapy-
Brain	Symptom	Index		
There	was	one	study	that	reported	the	development	of	the	NFbrSI-24	(Lai	et	al.,	
2014).		However	they	utilised	survey	results	from	a	previous	study	of	69	healthcare	
professionals	from	throughout	the	United	States	(Cella	et	al.,	2003)		in	the	
development	of	content	validity.		The	main	developmental	study	recruited	50	
patients	with	advanced	primary	brain	tumours	from	six	National	Comprehensive	
Cancer	Network	institutions	along	with	ten	physician	experts	(Lai	et	al.,	2014).		
Supportive	Care	Needs	Survey	–	34	plus	brain	subscale		
There	were	two	studies	that	reported	the	development	of	the	SCNS34-BS	(Janda	et	
al.,	2008,	2006)	designed	to	look	at	supportive	care	needs.	The	first	study	focused	on	
content	validity	and	involved	18	patients	and	carers	in	item	generation	(Janda	et	al.,	
2006).	The	second	study’s	main	aim	was	to	look	at	supportive	care	needs,	however	
the	relationship	with	anxiety	and	depression	was	examined	and	this	aspect	provides	
an	assessment	of	construct	validity	(Janda	et	al.,	2008).		The	studies	were	completed	
with	a	supportive	care	service	in	a	region	of	Australia.	In	the	following	section,	
relevant	psychometric	properties	of	these	four	tools	will	be	evaluated.	
Evaluation	of	Psychometric	properties		
The	developmental	studies	and	their	psychometric	properties	are	outlined	in	Table	2	
and	the	quality	scoring	based	on	COSMIN	criteria	(Terwee	et	al.,	2012)	is	detailed	in	
Table	3.		
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Validity		
Content	validity	was	developed	in	all	tools	with	some	advised	approaches	such	as	
the	use	of	literature,	reference	to	other	tools	and	the	input	of	experts	as	well	as	end	
users	(de	Vet,	Terwee,	Mokkink,	&	Knol,	2011;	Reeve	et	al.,	2013;	Scholtes,	Terwee,	
&	Poolman,	2011).			Item	generation	was	completed	with	the	end	users	for	the	
SCNS34-BS	(Janda	et	al.,	2006),	MDASI	–	BT	(Armstrong	et	al.,	2005)	and	the	NFbrSI-
24	(Lai	et	al.,	2014)	however,	this	important	aspect	was	missing	from	the	Brain	PCI	
(Rooney	et	al.,	2014).			The	next	step	of	content	validity	should	undertake	a	more	
extensive	evaluation	to	assess	comprehensiveness	and	comprehensibility.		This	was	
evident	in	the	MDASI	–	BT	(Armstrong	et	al.,	2006)	and	the	NFbrSI-24	(Lai	et	al.,	
2014)	with	both	tools	utilising	qualitative	and	quantitative	methods.		The	MDASI	–	BT	
which	has	met	the	criteria	for	a	‘good’	rating	rather	than	‘excellent’,	as	there	were	
less	than	10	participants	from	the	end	users	(patients)	and	the	NFbrSI-24	was	rated	
as	‘excellent’.		
Another	aspect	of	validity	is	construct	validity,	or	hypothesis	testing,	which	is	
frequently	undertaken	with	QOL,	performance	status,	anxiety	and	depression,	or	
distress	(Richardson	et	al.,	2007).			The	three	studies	that	analysed	this	aspect	were	
rated	from	‘poor’	to	‘good’.			The	SCNS34-BS	examined	the	relationship	between	
supportive	care	needs	and	distress	utilizing	the	Hospital	Depression	and	Anxiety	
Scale	(HADS)	(Zigmond	&	Snaith,	1983).	Multivariate	logistic	regression	analysis	was	
performed	rather	than	recommended	test	of	a	correlation	co-efficient	resulting	in	
the	‘poor’	rating.		However,	it	should	be	acknowledged	this	was	not	the	stated	
purpose	of	the	study	and	this	did	demonstrate	a	relationship	between	these	
constructs.	The	NFbrSI-24	(Lai	et	al.,	2014)	was	rated	‘good’	rather	than	‘excellent’	as	
the	sample	size	was	<	100	and	the	MDASI-BT	was	rated	‘good’	rather	than	‘excellent’	
due	to	only	recruiting	from	one	centre	(Armstrong	et	al.,	2006).		
No	studies	undertook	measures	of	structural	validity,	however	as	HNA	is	a	likely	to	
be	a	formative	model,	as	need	is	comprised	of	many	unrelated	factors,	this	property	
is	not	relevant	(Terwee	et	al.,	2012).		There	were	no	studies	examining	cross-cultural	
validity.		
Reliability	
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The	SCNS34-BS	(Janda	et	al.,	2008,	2006)	and	the	Brain	PCI	(Rooney	et	al.,	2014),	did	
not	undertake	any	testing	of	reliability	in	the	reviewed	studies.	The	MDASI-BT	looked	
at	internal	consistency	for	each	sub-scale	(Armstrong	et	al.,	2006)	and	demonstrated	
‘excellent’	internal	consistency	within	the	recommended	range	(Mokkink	et	al.,	
2012).	The	NFbrSI-24	demonstrated	acceptable	internal	consistency	for	the	full	
symptom	index	however	the	treatment	side	effect	subscale	fell	slightly	below	
recommended	limits	(	=	0.65),	which	corresponds	to	a	‘fair’	rating	for	this	property		
(Mokkink	et	al.,	2012).	
The	inter-rater	reliability	and	test-retest	reliability	for	the	MDASI-BT	was	first	
reported	in	Armstrong	et	al.,	(2012).		As	this	review	is	focused	on	the	use	of	tools	as	
a	PROM	the	inter-rater	reliability	is	not	relevant.			The	test-retest	variable	was	
measured	on	a	subgroup	of	21	patients	using	Spearman	correlations	between	the	
two	time	points	and	the	analyses	supported	test-retest	reliability	but	it	was	an	
inadequate	sample	size	for	this	psychometric	property	(Mokkink	et	al.,	2012).	
However,	a	subsequent	study	of	92	individuals	undertook	test-retest	measurements	
at	24	hours	and	7	days	(Armstrong	et	al.,	2014).	This	demonstrated	good	congruence	
between	both	time	intervals	and	based	on	the	7-day	recall	and	a	sample	size	of	92,	a	
rating	of	‘good’	was	made	for	this	criteria.	Although	there	is	not	a	specific	time	
interval	advised	in	the	COSMIN	rating	scale	some	authors	advocate	an	interval	of	
about	two	weeks	(de	Vet	et	al.,	2011).		The	time	interval	must	be	balanced	between	
ensuring	respondents	do	not	remember	their	answers	and	the	stability	of	the	
patient’s	condition.	Measurement	error	was	not	specified	for	any	tool.		
Interpretability		
The	COSMIN	criterion	does	not	provide	ratings	for	this	property,	however,	the	
MDASI-BT	demonstrated	a	significant	correlation	with	inpatient	and	outpatient	
status	and	both	the	MDASI-BT	and	NFBrSI-24	demonstrated	a	significant	correlation	
between	symptoms	and	performance	status.		This	provides	the	ability	to	assign	
meaning	to	the	changes	through	commonly	understood	clinical	connotations.		
Responsiveness	was	not	reported	in	any	of	the	reviewed	studies.		
Generalizability		
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A	further	limitation	of	each	of	the	tools	assessed	is	that	they	have	all	been	developed	
and	tested	only	in	one	country,	which	may	impact	their	generalizability	to	other	
regions.	Even	though	all	were	developed	in	English,	meanings	can	have	cultural	and	
language	variations,	therefore	cross-cultural	validity	should	be	assessed.	The	MDASI-
BT	and	Brain	PCI	have	been	developed	for	our	target	group,	including	all	stages	of	
primary	brain	cancer	patients.	In	their	development,	the	NFbrSI-24	focused	on	only	
advanced	brain	tumours	and	the	SCNS34-BS	included	a	significant	proportion	of	
benign	tumours.				
The	MDASI-BT	and	the	NFbrSI-24	demonstrated	good	psychometric	properties	while	
both	the	Brain	PCI	and	SCNS34-BS	are	lacking	evidence	of	reliability	and	validity.		Of	
these	the	MDASI-BT,	as	developed	for	all	brain	cancer	patients,	would	be	most	
suitable,	however	additional	development	would	be	needed	to	encompass	the	
holistic	aspects	of	need.		
Evaluation	of	tools	for	use	as	a	Holistic	Needs	Assessment	tool	
We	summarised	the	details	of	the	evaluation	of	the	four	tools	identified,	in	relation	
to	their	quality	and	usefulness	as	a	HNA	tool	(Table	4).	The	first	criterion	was	to	
comprehensively	represent	the	common	domains	of	need.	The	original	SCNS-34	was	
designed	using	a	theoretical	framework	developed	with	five	constructs	of	need	
(Bonevski	et	al.,	2000).	Although	this	was	not	specifically	examined	for	the	additional	
brain	tumour	subscale,	in	combination	with	SCNS-34,	there	is	representation	of	the	
common	domains	of	need	(Janda	et	al.,	2008).	Similarly,	the	MDASI-BT	structure	and	
design	was	underpinned	by	a	theoretical	framework	of	individual	characteristics	of	
patient	burden	and	symptoms	(Armstrong	et	al.,	2006).	This	tool	was	designed	to	
assess	emotional	and	physical	symptoms	with	aims	of	evaluating	treatments	and	
planning	interventions	to	alleviate	symptoms,	therefore	the	focus	is	on	physical	and	
psychological	problems	and	other	domains	of	need	are	not	covered.		The	Brain	PCI	
appeared	to	cover	the	majority	of	the	relevant	domains	of	need,	but	the	process	for	
comprehensively	representing	these	was	not	discussed	(Rooney	et	al.,	2014).	The	
NFbrSI-24,	similar	to	the	MDASI-	BT,	was	developed	as	a	symptom	questionnaire	
rather	than	a	HNA	tool	therefore	the	focus	was	on	physical	and	emotional	
symptoms.		
	 Page 11 of 34  
The	SCNS34-BS	did	not	report	any	details	of	the	user	acceptability	or	how	usable	this	
might	be	in	a	clinical	situation.		The	NFbrSI-24	and	MDASI-BT	did	not	formally	assess	
acceptability,	although	completion	time	of	the	MDASI-BT	was	noted	to	take	
approximately	10	minutes.		The	Brain	PCI	did	examine	user	and	assessor	
acceptability	and	found	that	despite	the	presence	of	cognitive	difficulties	in	many	
participants,	91%	of	patients	found	this	questionnaire	‘easy’	or	‘very	easy’	to	
complete.		The	Brain	PCI	was	rated	positively	from	clinicians	with	19/21	feedback	
forms	rating	the	tool	as	useful,	however	14/21	stated	that	increased	consultation	
time,	although	this	was	not	formally	assessed	(Rooney	et	al.,	2014).		
In	the	context	of	the	evaluation	criteria	for	an	HNA	tool,	the	Brain	PCI	appears	most	
suitable	due	the	assessment	of	most	of	the	domains	of	need	and	the	assessment	of	
the	usability	from	the	perspective	of	the	patient	and	clinician.	
Discussion	
This	is	the	first	review	of	assessment	tools	developed	for	brain	cancer	patients	that	
may	be	used	to	assess	unmet	needs	or	concerns.			This	review	found	four	tools	which	
could	be	considered	for	HNA,	however	none	had	strong	psychometric	properties,	
and	the	two	that	were	developed	for	HNA	had	only	minimal	psychometric	testing.	
Some	of	the	studies	that	developed	these	tools	were	conducted	prior	to	publication	
of	the	COSMIN	criteria	so	other	specifications	may	have	guided	their	methodology,	
however	these	criteria	now	present	a	reliable	and	valid	process	to	evaluate	tools	
supporting	the	choice	of	this	criteria.	The	lack	of	psychometric	testing	is	not	unique	
to	brain	cancer	and	is	reflected	in	other	reviews	of	HNA	for	generic	cancer	
(Richardson	et	al.,	2007)	or	other	specific	cancers	such	as	lung	cancer	(Maguire	et	al.,	
2013).	As	previously	discussed,	most	authors	support	the	need	for	psychometric	
testing	of	HNA,	however	the	authors	who	developed	the	Brain	PCI	(Rooney	et	al.,	
2014)	shared	the	alternative	viewpoint	presented	by	Garssen	&	de	Kok,	(2008).		They	
assert	that	the	priority	for	research	on	HNA	tools	should	not	be	the	development	of	
the	psychometric	properties	but	a	focus	on	the	feasibility	of	usage	of	screening	tools	
in	clinical	practice	and	the	effects	of	decisions	made	by	the	health	care	providers,	
ultimately	focused	on	the	outcomes	for	patients.			
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	While	it	might	be	questioned	whether	tools	that	are	developed	as	‘symptom	
questionnaires’	such	as	the	MDASI-BT	or	the	NFbrSI-24	were	appropriate	to	
consider,	they	were	included	for	a	number	of	reasons.		There	were	a	lack	of	PROMs	
which	facilitated	the	patient’s	identification	of	concern	in	brain	cancer.	In	addition,	
the	use	of	a	validated	symptom	scale	in	combination	with	targeted	problem	checklist	
focused	on	the	other	domains	of	need	is	an	approach	that	has	been	adopted	for	
generic	cancer	needs	assessment	in	Canada	(Canadian	Partnership	Against	Cancer,	
2012;	Watanabe	et	al.,	2012).			
User	acceptability	for	both	the	patient	and	clinician	is	a	key	component	when	
developing	questionnaires	or	assessment	tools	for	clinical	use.	The	ideal	instrument	
should	assess	the	perceived	burden,	usefulness	and	meaning	in	relation	to	improving	
the	existing	strategies	for	detection	of	unmet	need.		User	acceptability	and	burden,	
is	important	for	all	PROMs,	but	as	previously	highlighted,	in	brain	cancer	this	is	
particularly	important	as	completion	can	be	impacted	by	the	neurocognitive	
impairments.	In	clinical	trials	for	brain	cancer	patients,	QOL	form	completion	can	be	
poor,	with	either	no	form	completed	or	missing	items	(Dirven	et	al.,	2014;	Walker	et	
al.,	2003).		A	recent	study	in	Germany	with	patients	diagnosed	with	glioma	
highlighted	that	even	with	support	in	clinics	up	to	10%	of	participants	erroneously	
completed	the	SCNS-34	and	this	rises	to	20%	without	support	(Renovanz	et	al.,	
2016).		They	highlighted	structure	and	comprehension	as	contributing	factors	but	
also	noted	that	if	patients	were	distressed	more	errors	occurred.			There	is	also	data	
that	suggests	that	if	clinicians	find	the	questionnaires	cognitively	demanding,	
burdensome	or	not	clinically	relevant,	their	support	of	implementation	and	response	
to	any	PROM	could	be	sub-optimal	(Gilbert,	Sebag-Montefiore,	Davidson,	&	Velikova,	
2015).	There	clearly	needs	to	be	a	balance	between	ensuring	the	relevant	problems	
of	a	neuro-oncology	population	are	assessed,	while	minimising	burden.		
The	findings	suggest	two	potential	options	that	could	be	considered	for	HNA	in	Brain	
cancer.		The	Brain	PCI,	out	with	its	psychometric	properties,	demonstrated	moderate	
to	strong	characteristics	in	relation	to	HNA	quality	criteria	and	with	additional	
psychometric	testing	may	offer	one	approach.		Alternatively,	the	MDASI	–	BT	
demonstrated	the	strongest	psychometric	properties	and	could	provide	the	basis	for	
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an	alternative	approach.		This	tool		could	be	combined	with	a	more	holistic	
assessment,	similar	to	the	approach	the	Canadian	Partnership	Against	Cancer	(2012)	
that	uses	the	Edmonton	Symptom	Assessment	System	together	with	the	Canadian	
Problem	Checklist.		However,	based	on	the	results	of	this	review,	that	although	
progress	has	been	made,	no	tool	provides	a	comprehensive	approach	in	identifying	
needs	without	further	development.		
Recommendations	for	further	research		
Recently,	an	international	multidisciplinary	working	group	has	been	set	up	to	
evaluate	and	provide	guidance	on	the	use	of	patient	reported	outcomes	in	neuro-
oncology	(Dirven	et	al.,	2018).		This	may	provide	valuable	information	on	the	use	of	
HNA	or	provide	direction	on	what	other	PROMs	could	generate	high	quality	evidence	
to	help	evaluate	the	impact	of	HNA	processes	in	future	research.		
In	addition,	to	the	areas	already	discussed,	there	are	many	other	aspects	of	HNA	in	
brain	cancer	which	would	benefit	from	research.	The	use	of	electronic	HNA	are	
increasingly	used	and	may	provide	a	basis	for	improving	compliance	and	providing	
this	information	to	a	variety	of	health	care	providers.		Electronic	PROMs	are	
acceptable	to	patients	and	have	the	potential	to	provide	a	variety	of	modes	(e.g.	
internet	based,	hand	held	devices)	and	could	be	personalised	based	on	patient	
preferences	or	capabilities	(Gilbert	et	al.,	2015).	However,	the	IT	systems	to	collect	
this	data	in	a	meaningful,	accessible,	and	secure	ways	need	to	be	developed	and	
tested.			
There	is	also	a	need	to	look	at	studies	comparing	different	pathways	for	HNA	and	the	
impact	of	this	process.		For	example,	where	is	it	completed,	at	what	point	in	the	
treatment	trajectory	and	which	health	or	social	care	provider	receives	and	reviews	it.	
Most	importantly,	research	should	focus	on	the	impact	of	HNA	in	improving	
outcomes	such	as	reducing	distress	or	increasing	wellbeing.		
Strengths	and	Limitations	
This	was	a	rigorously	conducted	review	of	tools	that	may	support	HNA	in	brain	
cancer.	This	review	has	some	limitations.	The	diversity	and	quality	of	methodological	
approaches	was	challenging	when	comparing	tools.		There	were	also	differences	in	
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the	aims	of	tools	and	although	they	all	aimed	to	measure	some	aspects	of	needs	or	
problems,	some	may	have	not	been	designed	specifically	to	undertake	a	holistic	
assessment.		Despite	this	limitation,	their	inclusion	was	useful,	as	if	an	existing	tool	
was	to	be	adapted	–	these	could	be	considered.	
Conclusion		
Providing	supportive	care	and	meeting	the	needs	of	patients	with	brain	cancer	who	
in	many	cases	have	a	poor	prognosis,	is	challenging.		HNA	has	been	identified	as	an	
important	strategy	to	facilitate	this	process.	This	review	has	provided	a	
comprehensive	overview	of	the	content	and	measurement	properties	of	four	tools	
that	could	be	used	for	HNA	in	brain	cancer.			Similar	to	other	reviews	of	holistic	
needs	assessment	tools	in	cancer,	this	review	identified	a	variety	of	tools	for	
assessing	needs,	however	there	is	currently	a	lack	of	evidence	to	support	what	might	
be	the	best	tool	or	even	consensus	on	how	to	evaluate	this	in	a	clinical	setting	
(Higginson,	Hart,	Koffman,	Selman,	&	Harding,	2007;	Richardson	et	al.,	2007;	Wen	&	
Gustafson,	2004).	It	is	clear,	due	to	the	lack	of	a	clearly	suitable	tool	in	this	area,	that	
the	evidence	base	to	develop	this	area	of	supportive	care	is	limited.	Ideally	a	fit-for-
purpose,	psychometrically	robust,	and	context-specific	tool	should	be	developed	
specifically	for	brain	cancer	patients,	to	be	used	in	everyday	practice	to	allow	for	
meaningful	communication	to	identify	supportive	care	needs.	The	lack	of	a	tool,	
which	adequately	meets	these	requirements,	supports	the	need	to	further	explore	
how	HNA	can	be	performed	in	brain	cancer	patients	to	optimize	this	intervention.		
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	Box	1	–	Definitions	of	Psychometric	properties	for	PROMs			
Psychometric	property		 Definition		 Considerations	
Validity	 The	degree	to	which	an	HR-PRO	instrument	measures	
the	construct(s)	it	purports	to	measure	
	
Content	validity:	 Content	validity	seeks	to	assess	if	the	component	parts	
and	tool	measures	what	it	is	intended	to		
Initial	development	through	the	literature,	expert	opinion	and	patient	input	
Refinement	of	item	selection	and	phrasing	through	end	users		
Hypothesis	testing	or	
(Construct	validity):	
The	degree	to	which	the	scores	of	the	PROM	are	
consistent	with	hypotheses	(for	instance	with	regard	to	
internal	relationships,	relationships	to	scores	of	other	
instruments,	or	differences	between	relevant	groups)	
based	on	the	assumption	that	the	tool	validly	measures	
the	construct	to	be	measured.		
	
Any	measurement	tools	used,	as	a	comparator,	should	have	adequate	
measurement	qualities.			
Two	criteria	should	be	met;	1)	that	hypotheses	should	be	stated	in	the	methods	
including	magnitude	and	2)	75%	of	the	results	are	in	accordance	with	these	
hypotheses	which	should	be	reported	as	a	correlation		
	
Structural	validity	 The	degree	to	which	the	scores	of	an	PROM	instrument	
are	an	adequate	reflection	of	the	dimensionality	of	the	
construct	to	be	measured	
This	is	appropriate	for	use	when	a	measurement	tool	is	based	on	reflective	model		-	
not	for	those	based	around	a	formative	model.		HNA	is	likely	to	be	considered	
formative	due	to	independent	contributing	factors.		
Cross-cultural	validity	 The	degree	to	which	the	performance	of	the	items	on	a	
validity	translated	or	culturally	adapted	PROM	
instrument	are	an	adequate	reflection	of	the	
performance	of	the	items	of	the	original	version	of	the	
PROM	instrument	
	
	 	
Reliability	 Refers	to	the	stability	of	responses	over	time	or	between	
respondents	(reproducibility)	and	the	consistency	of	the	
items	in	the	tool.		Reliability	contains	two	measurement	
properties:	Internal	consistency	and	test-retest	reliability				
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Internal	consistency:	 The	extent	to	which	items	in	a	questionnaire	scale	are	
correlated,	thus	measuring	the	same	concept.		
	
The	most	common	method	used	is	Cronbach's	alpha	and	it	should	be	calculated	for	
each	dimension	separately.		
Reliability:	Test–retest	
reliability:	
The	degree	to	which	repeated	measurements	in	stable	
persons	provide	similar	answers.		
	
Correlation	values	between	administrations	of	0·70	are	considered	acceptable.	Two	
weeks	is	often	considered	an	acceptable	time	gap	
Measurement	error:	 Refers	to	changes	in	the	scores	of	the	tool	that	are	not	
attributed	to	a	true	change	in	the	construct	to	be	
measured.		
	
This	will	require	two	measurements	usually	about	2	weeks	apart	(to	prevent	recall)	
and	the	construct	to	be	measured	should	remain	stable.	
Responsiveness:	(also	called	
sensitivity)		
Refers	to	the	ability	of	a	tool	to	detect	changes	over	
time,	which	correlates	with	the	construct	being	assessed.		
	
	
Interpretability	 Refers	to	the	ability	to	attach	meaning	(for	example	
commonly	understood	concepts)	to	the	tools	results	or	
changes	in	the	tools	results.		This	looks	at	the	degree	to	
which	one	can	assign	qualitative	meaning	to	quantitative	
scores.		
	
An	important	concept	within	this	is	the	ability	to	detect	the	MIC	which	is	the	lowest	
level	at	which	a	patient	feels	a	change	is	important	to	them.	Interpretation	of	this	is	
gives	a	clinically	important	level	for	clinicians	assessing	the	effects	of	treatments	or	
need	for	intervention	(de	Vet	et	al.,	2011).	
	
	 	 	 	
HR-PRO	=	Health-related	patient	reported	outcome,	PROM	=	patient	reported	outcome	measurement,	HNA	=	holistic	needs	assessment,	MIC	=	minimal	important	change		
	
Derived	from	the	COnsensus-based	Standards	for	the	selection	of	health	Measurement	INstruments	(COSMIN)	checklist	(Mokkink	et	al.,	2012;	Mokkink	et	al.,	2010)		
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Box	2	–	Criteria	for	Tools	for	Holistic	Needs	Assessment	
Needs	
assessment	
characteristic			
Definition		 Recommendations	if	applicable		 Rating		
Planned	use	of	
tool		
	
Tools	can	be	primarily	
designed	for	research	or	
clinical	use.		The	approach	to	
needs	assessment	in	most	
cases	will	be	with	a	specific	
tool	for	this	purpose		
	
	
A	holistic	needs	assessment	tool	should	
be	designed	with	the	purpose	of	
assessment	of	patient	needs	for	clinical	
purposes	and	developed	and	tested	for	
the	intended	population	(Richardson,	
Medina,	Brown,	&	Sitzia,	2007).	–	
however	some	strategies	such	as	
Canadian	Partnership	Against	Cancer	
(2009)	have	advocated	symptom	
assessment	with	an	amended	problems	
checklist	as	a	reasonable	approach	
	
Weak	–	primary	
purpose	not	needs	
assessment	and/or	not	
developed	for	clinical	
use		
Strong	–	primary	
purpose	is	brain	tumour	
patient	needs	
assessment	in	clinical	
practice		
Identification	of	
the	dimensions	
of	need	
	
The	literature	clearly	
identified	a	number	of	
domains	to	be	considered	
which	included	physical,	
psychological,	social,	
emotional,	financial,	sexual,	
functional	and	spiritual	
domains	in	HNA	(Cleeland	et	
al.,	2000;	Johnsen,	Petersen,	
Pedersen,	&	Groenvold,	2011;	
Schofield,	Gough,	Lotfi-Jam,	&	
Aranda,	2012;	Waller,	Girgis,	
Currow,	&	Lecathelinais,	
2008).		
HNA	tools	should	assess	the	
multidimensional	impact	of	cancer.		
Within	this	criterion,	reference	to	a	
theoretical	or	conceptual	framework	
can	help	to	identify	factors,	which	are	
important	to	assess.		
	
Weak	–	no	theoretical	
framework,	not	
covering	the	majority	
domains	of	needs			
Moderate	–	covering	
majority	of	domains	of	
needs	but	no	
theoretical	framework		
Strong	–	theoretical	
framework	and	
covering	the	majority	
domains	of	needs			
Psychometric	
properties		
Demonstrate	strong	
psychometric	properties	
	
The	COSMIN	criteria	were	chosen	to	
assess	the	psychometric	properties	as	
described	in	the	previous	section.		
	
Weak	–	Little	evidence	
of	psychometric	
properties	
Moderate	–	some	
limited	evidence	of	
psychometric	
properties	
Strong	–	good	evidence	
of	psychometric	
properties		
	
4	Be	user-
friendly	
	
A	number	of	elements	should	
be	considered	such	as	the	
time	to	complete,	ease	of	
completion,	comprehension,	
and	perceived	usefulness	as	a	
tool	to	communicate	needs.		
	
	
	
	
	
It	is	generally	agreed	that	reading	level	
for	patient	reported	health	outcome	
measures	should	not	exceed	12	years	
of	age	(Streiner	&	Norman,	2008).	In	
patients	with	primary	brain	tumours,	
cognitive	impairment	is	very	common	
with	54%	demonstrating	some	form	of	
cognitive	impairment	often	related	to	
language,	memory	and	attention	
(Zucchella,	Bartolo,	Di	Lorenzo,	Villani,	
&	Pace,	2013).	Lai,	Jensen,	et	al.,	(2014)			
	
	
Weak	-	no	user	
assessment		
Moderate	–	some	
subjective	assessment	
from	users		
Strong	–		subjective	
assessment	from	users	
and	objective	
assessments	(for	
example	encompassing	
assessment	of	reading	
level,	acceptably	form	
completion	
requirements	and	recall	
time	frame)	
	
	
5:	Be	assessor	
friendly	
	
The	time,	energy	and	
resources	for	those	receiving	
and	responding	on	
questionnaires	needs	to	be	
Vodermaier,	Linden,	&	Siu,	(2009)	
highlight	that	a	short	questionnaire	of	
5-20	items	may	have	a	moderate	
chance	of	use	in	busy	clinics	compared	
Weak		-	no	assessment		
Moderate	–	some	
subjective	assessment	
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considered	(Maguire	et	al.,	
2013).	This	criterion	relates	to	
the	ease	of	interpretation	and	
usefulness	to	clinicians	to	
support	HNA.		It	should	also	
consider	variables	that	may	
affect	health	care	resources	
such	as	does	it	add	time	to	the	
overall	consultation	
	
	
	
	
to	longer	formats,	and	there	may	be	
resources	associated	with	scoring	
longer	questionnaires	if	required.		
	
	
	
	
	
	
	
from	clinicians	or	
objective	assessment		
Strong	–		subjective	
assessment	from	users	
and	objective	
assessments	(for	
example	encompassing	
usefulness,	ease	of	
interpretation	and	
resource	implications	
	
,	HNA	=	holistic	needs	assessment,	COSMIN	=	COnsensus-based	Standards	for	the	selection	of	health	Measurement	INstruments	
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Figure	1	–	Systematic	Search		
 
 
CINAHL	
	
5385	Non	Duplicate	Citations	Screened		
(526	duplicates	removed)	
Inclusion	and	Exclusion	
Criteria	applied	
5242	Articles	excluded	
after	Abstract/Title	Screen	
143	Full-text	articles	
assessed	for	eligibility	
134	Full-text	articles	
excluded	after	Full	Text	
9	Full	Text	Articles	
Included	
MEDLINE		
	
PsycINFO	
	
Additional	records	
through	other	sources		
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Table	1	–	Summary	of	tool	properties	
Tool		 Purpose	 Domains	 N	of	items	 Response	options		 Recall	
period			
Scoring		 Time	to	
administer		
Brain	
PCI	
HNA		
CU			
Practical,	family,	emotional,	spiritual	
and	physical	–	with	options	to	
request	referral	and	space	to	ask	
questions.		
58	plus	
4	free	text	
questions		
Tick	box	to	‘issues	that	
have	been	a	concern’	
‘recently’	 Tick	box	only		 60%	of	
patient	
report	<15	
minutes	
MDASI-
BT	
SYM	
CU	&	R		
Six	affective,	cognitive,	focal	
neurologic	deficits,	constitutional,	
generalized	symptom,	and	a	
gastrointestinal	related	factor.	
	
29	 Scaling	–	A	11	point	Likert	
scale	in	relation	to	the	
presence	and	severity	of	
each	symptom	in	the,	with	
0	being	‘‘not	present’’	and	
10	being	‘‘as	bad	as	you	
can	imagine”		
11	point	Likert	scale	in	
relation	to	level	of	
interference.	
Last	24	
hours	
Individual	symptoms	scored	none,	
mild	(1-4),	moderate	(>	5)	and	severe	
(>	7)	and	average	for	overall	rating	of	
symptom	burden	
Less	than	10	
minutes		
NFbrSI-
24	
SYM		
CU	&	R	
Three	subscales;	disease	related	
symptoms	(physical	and	emotional),	
treatment	side	effects	and	
functional/wellbeing.	
24		 Scaling	-	A	five-point	
intensity	scale	based	on	
‘how	it	applies	to	you’	from	
‘not	at	all’	to	‘very	much’	
Last	7	
days	
Individual	symptoms/concerns	are	
scored	with	higher	scores	reflecting	
less	symptoms	and	concerns	
(negatively	worded	items	are	
NR	
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reversed).		Each	domain	has	a	score	
as	well	as	overall	questionnaire.	
SCNS34-
BS	
HNA		
CU	
	
Format	-	Brain	specific	'add	on'	
questionnaire	to	SCNS34.		
Five	domains	SCNS34	(Psychological,	
Health	system	and	information,	
physical	and	daily	living,	patient	care	
and	support,	sexuality);	care	needs.	
The	brain	subscale	has	no	grouping	
of	domains		
	
50	 Scaling	-	Five	categorical	
responses,	ranging	from	
high	need	to	no	need.			
	
Last	
month	
Patients	grouped	according	no	or	low	
needs	and	those	with	moderate	or	
high	needs.			
	
NR	
Brain	PCI	–	Brain	Patient	Concern	Inventory,	MDASI	–	BT	–	MD	Anderson	Symptom	Inventory	and	Brain	Tumor	Module,	NFBrSI-24	-	24-item	National	Comprehensive	Cancer	Network/Functional	
Assessment	of	Cancer	Therapy-Brain	Symptom	Index,	SCNS34-BS	–	Supportive	Care	Needs	Survey	(Short	Form)	with	Brain	Subscale		
HNA	=	holistic	needs	assessment,	SYM	=	symptom	assessment,	CU	=	clinical	use,	R	=	research	or	clinical	trial	use				
NR	=	not	reported			
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Table	2–	Sample	characteristics	of	developmental	studies	and	psychometric	properties			
tool		 Source		 Sample	characteristics		 Content	Validity	process		 Hypothesis	testing/construct	
validity	
	
Internal	consistency	 Reliability	 Interpretability			
location	 N*	
(subgroups	if	
applicable)		
	
Sex	(%)	 Age	in	years	range	
(%)		
Or	mean	=	x		
	
Brain	PCI	 (Rooney	et	
al.,	2013)	
UK	
	
One	cancer	centre		
	
	
	
53		
		
M	(55),	F	(47)	 18-34	(11),		
35-59	(62),	
>60	(21)	
• Other	tools	
• Expert	opinion	
NR	 NR	 NR	 NR	
MDASI	–	
BT	
(Armstrong	
et	al.,	2005)	
USA		
	
(multi	location)		
	
	
	
	
20	
(16	=	HCP	
4	=	PBT	or	C)	
NR	 NR	 • Theoretical	
framework		
• literature	review	
• Expert	opinion	
• CVI	>	0.80)	
NR	 NR	 NR	 NR	
MDASI	–	
BT	
(Armstrong	
et	al.,	2006)	
USA	
	
One	cancer	centre		
	
	
	
	
201		
	
		
M	(57),	F	(43)	
	
18-45	(52)	
45-84	(48)	
	
NR	 Principal	component	analysis	
endorsed	the	six	underlying	
constructs	
	
6	symptom	scales	and	
interference	scale	
(Cronbach’s	α	=	0.87,	
0.82,	0.72,	0.81,	0.69,	
0.67	and	0.91)	
NR		 Correlation	with	KPS		p		<	0.001	
And	IP	vs	OP		p		<0.0005		
MDASI	–	
BT	
(Armstrong	
et	al.,	2012)	
USA	
	
One	US	cancer	
centre	
	
	
	
	
230	
(115	PBT	and	C	
dyads)	
	
	
(Test–retest	
subgroup	N	=	
21	PBT)	
	
PBT	=	M	(63),	
F	(37)		
C	=	M	(27),	F	
(73)	
x	=	48.2	 NR	 NR	 NR	 mean	symptom	
severity,	r	=	0.952,	p	
<	0.0001;	mean	
interference,	r	=	
0.783, p	
<	0.0001)		
2	hours	
	
	
NR	
MDASI-	
BT	
(Armstrong	
et	al.,	2014)	
USA	
	
One	US	cancer	
centre	
	
100	
	
92	completing	
three	time-
points	
	
M	(62),	F	(38)	 19-77	
x	=	48	
NR	 NR	 NR	 Day	7	Cronbach’s	α	=	
Symptoms	(overall)	
0.91,	Affective	0.86,	
Cognitive	0.94,	
Neurologic	0.74,	
Treatment	related	
0.53,	Generalized	
0.68,	disease	GI	
(composite)	0.42,	
Interference	
(overall)	0.93,	WAW	
0.89,	
	REM	0.88	
	
NR	
NFbrSI-
24	
(Cella	et	al.,	
2003)	
USA	
	
Multiple	sites		
	
69	(all	HCP)	
		
NR	 NR	 • Literature	review	
• Other	tools	
• Expert	opinion	
(ranking)		
NR	 NR	 NR	 NR	
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Brain	PCI	–	Brain	Patient	Concern	Inventory,	MDASI	–	BT	–	MD	Anderson	Symptom	Inventory	and	Brain	Tumor	Module,	NFBrSI-24	-	24-item	National	Comprehensive	Cancer	Network/Functional	Assessment	of	Cancer	Therapy-Brain	Symptom	Index,	SCNS34-BS	–	Supportive	Care	Needs	Survey	(Short	Form)	with	Brain	
Subscale		
NR	=	details	not	reported	in	article			
M=	male,	F	=	female	
PBT	=	primary	brain	tumour	patient	C	=	Carer	HCP	=	health	care	professional			
X	=	mean	
CVI	=	content	validity	index		
DV	=	divergent	validity,	CV	=	convergent	validity		
FACT	-	Functional	Assessment	of	Cancer	Therapy	
KPS	–	Karnofsy	Performance	status,	ECOG-PS	=	Eastern	Co-operative	Oncology	Group	Performance	Status	
REM	=	relate-enjoy-mood,	WAW=	walk-activity-work	
*	All	primary	brain	cancer	patients	unless	otherwise	specified		
**Study	also	reported	results	of	70	carers	separately		
	
	
	
	 	
	
	
	
	
NFbrSI-
24	
(Lai,	Jensen,	
et	al.,	2014)	
USA	
	
Six	cancer	
centres/hospitals		
	
50	
	
plus	10	HCP	(for	
Content	validity	
ONLY)	
	
	
	
M	(66),	F	(34)	
	
NR	
x	=	52.2		
	
• Patient	survey	to	
refine	items	
from	20	to	24		
• Expert	opinion	
(domains)		
	
CV	
FACT	General,	physical,	social,	
emotional,	and	brain	tumour–
specific	concerns	(ρ	=	0.59,	
0.57,	0.40,	0.35,	and	0.50,	
respectively;	Ps	<	0.05)	
full	tool;	disease	related	
symptom	subscale;	
functional	wellbeing	
subscale;	treatment	
side	effect	scale	(r	=	
0.84,	0.79,	0.89,	0.65)	
	
NR	 The	NFBrSI-24	and	its	subscales	
significantly	differentiated	
patients	with	different	levels	of	
functional	status	-	ECOG	–	PS:		
(F2,47	=	8.21; p	<		.001)		
SCNS34-
BS	
(Janda	et	al.,	
2006)	
Australia	
	
One	support	group		
36	
(N	=	18	C,		
18	PBT)		
	
	
	
M	(30.5),	F	
(69.5)	
NR*	 • Literature	review	
• Expert	input	
• Focus	groups	
• Interviews		
	
NR	 NR	 NR	 NR	
SCNS34-
BS	**	
(Janda	et	al.,	
2008)	
Australia	
	
Mailing	list	of	
support	group	
	
	
	
	
	
	
75		
	
	
M	(46),	F	(54)	 <	50	(53.5)	
>50	(46.5)		
NR	 Patient	adjusted	odds	ratio	
with	patients	categorised	as	
high	need	(95%	CI)	
Depression	>	11	=	OR	2.11	(CI	
-	1.10-4.03)	
Anxiety	>	11	=	OR	2.89	(CI-	
1.29-6.45)	
	
NR	 NR	 NR	
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Table	3–	Psychometric	testing	quality	rating		
	
Evaluated	
measurement	
properties		
Content	
Validity	
Hypothesis	
testing	
Internal	
consistency	
Reliability	test	
retest	
Brain	PCI	 Poor	 NA	 NA	 NA	
MDASI	–	BT	 Good		 Good	 Excellent	 Good	
NFbrSI-24	 Excellent	 Good	 Fair	 NA	
SCNS34	–	BS		 Fair	 Poor	 NA	 NA	
	
Brain	PCI	–	Brain	Patient	Concern	Inventory,	MDASI	–	BT	–	MD	Anderson	Symptom	Inventory	and	Brain	Tumor	Module,	NFBrSI-24	-	24-item	National	Comprehensive	Cancer	Network/Functional	Assessment	of	Cancer	Therapy-Brain	Symptom	
Index,	SCNS34-BS	–	Supportive	Care	Needs	Survey	(Short	Form)	with	Brain	Subscale,	NA	=	not	assessed	
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Table	4	–Holistic	Needs	Assessment	Tool	Rating		
Measure			 Source		 Purpose		 Dimensions	 Psychometric	
properties	
User	acceptability	(methods	and	
results)	
Assessor	Acceptability	(method	and	results)	 Overall	assessment		
Brain	PCI	 (Rooney	et	al.,	
2013)	
Strong	-	has	been	developed	for	
needs	assessment	with	only	brain	
cancer	patients	
	
	
	
Moderate-	recognised	domains	
covered,	facility	to	add	questions	
around	needs.	No	theoretical	or	
conceptual	framework.		
Weak		 Moderate	-	feedback	from	
patients	sought	on	
comprehensiveness	and	ease	of	
completion	
	
	
Moderate	-	feedback	from	clinicians	sought	
and	felt	useful.		Interpretation	as	tick	box	
format	straightforward.		Verbal	reports	of	
increased	time	but	not	empirically	assessed	
This	tool	has	very	little	psychometric	testing.	It	
is	the	only	tool	to	examine	user	and	assessor	
acceptability	
MDASI-	BT	 (Armstrong	et	
al.,	2005)	
(Armstrong	et	
al.,	2006)	
	(Armstrong	et	
al.,	2012)	
(Armstrong,	et	
al.,	2014)	
Weak	-	has	been	developed	for	
primary	brain	cancer	patients	but	
focus	on	symptoms	
Weak	-	Has	only	focused	on	
psychosocial	and	physical	symptoms.	
Scaling	of	intensity	and	interference.		
Conceptual	framework	used	
Strong		 Weak	-	time	frame	for	completion	
10	minutes	but	no	user	subjective	
feedback		
Weak-	no	supporting	data	on	interpretability	
or	perceived	usefulness	or	ease	of	use	
This	tool	demonstrates	good	psychometric	
testing	but	focuses	on	symptoms	and	omits	
some	important	aspects	of	need.		There	has	
been	no	evaluation	of	patient	or	assessor	
perceptions	
	
	
	
NFbrSI-24	 (Cella	et	al.,	
2003)	
(Lai,	Jensen,	et	
al.,	2014)	
Weak	-	has	been	developed	for	
primary	brain	cancer	patients	but	
focus	on	symptoms	and	concerns	–	
but	has	excluded	items	of	concern	
not	related	to	disease	or	treatment	
such	as	financial	concerns		
Weak	-	Has	only	focused	on	general	
wellbeing,	psychosocial	and	physical	
symptoms	or	concerns.	Scaling	of	
intensity		
Strong		 Weak		-	no	reported	data	 Weak-	no	supporting	data	on	interpretability	
or	perceived	usefulness	or	ease	of	use	
This	tool	demonstrates	good	psychometric	
testing	but	focuses	on	symptoms	and	omits	
some	important	aspects	of	need.		There	has	
been	no	evaluation	of	patient	or	assessor	
perceptions	
	SCNS-34	BS	 (Janda	et	al.,	
2006)	
(Janda	et	al.,	
2008)	
Strong	-	is	designed	for	needs	
assessment	in	a	brain	tumour	
population		
	
	
Moderate-	recognised	domains	covered	
and	scaling	of	level	of	need.	No	
theoretical	or	conceptual	basis	
weak	 Weak	-	no	reported	data		 Weak-	no	supporting	data	on	interpretability	
or	perceived	usefulness	or	ease	of	use	
This	tool	demonstrates	minimal	psychometric	
testing	and	good	coverage	of	HNA	but	has	not	
examined	user	or	assessor	characteristics	
	
Brain	PCI	–	Brain	Patient	Concern	Inventory,	MDASI	–	BT	–	MD	Anderson	Symptom	Inventory	and	Brain	Tumor	Module,	NFBrSI-24	-	24-item	National	Comprehensive	Cancer	Network/Functional	Assessment	of	Cancer	Therapy-Brain	Symptom	Index,	SCNS34-BS	–	Supportive	Care	Needs	Survey	(Short	Form)	with	Brain	
Subscale	,	HNA	–	Holistic	Needs	Assessment	
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Supplementary	Material	(Appendix	S1)	-	Medline	Search	Query		
	
	
 
Monday, February 26, 2018 11:06:49 AM 
 Query Results 
S 1 (MH "Brain Neoplasms+") 137,481 
S 2 
(MH "Needs Assessment") OR 
(MH "Symptom Assessment") 
OR (MH "Self-Assessment") 40,841 
S 3 
(MH "Patient Outcome 
Assessment+") 4,802 
S 4 
TI (inventory or tool* or 
measure* or instrument* ) OR 
AB ( inventory or tool* or 
measure* or instrument*) 3,384,453 
S 5 S2 OR S3 OR S4 3,417,451 
S 6 S1 AND S5 11,337 
S 7 
S1 AND S5 Limiters - Human; 
Age Related: All Adult: 19+ 
years  
Search modes - 
Boolean/Phrase 4,926 
	
	
